



56%

Tigermed has supported the development of 56% of innovative drugs approved by the NMPA* from 2016 to 1H2022.

Tigermed

is a leading full-service global CRO for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, we are devoted to moving our customers through their development journey efficiently and cost-effectively.





The CRO that is Large Enough to Deliver yet Small Enough to Care



 $27_{\text{Offices \& Sites}}$

54 Countries

 $9,500+_{Global\ Employees}$

 $3,200+_{Clinical\ Trials}$

We Deliver Your Study with Excellence and Commitment

Regulatory Affairs Medical Writing Clinical Monitoring Data Management Statistical Analysis Medical Imaging
Pharmacovigilance
Medical Translation
Quality Assurance
Functional Service

Medical Device & IVD Site Management Project Management Real World Study Patient Recruitment

